ELTX furnishes Q3 2025 results press release as Exhibit 99.1

Rhea-AI Filing Summary

Elicio Therapeutics (ELTX) filed an 8-K announcing financial results for the quarter ended September 30, 2025 and providing corporate updates. The company furnished a press release as Exhibit 99.1 with additional details.

The information furnished, including Exhibit 99.1, is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001601485false11/13/202500016014852025-11-132025-11-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 13, 2025

Elicio Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-39990			11-3430072
(State or other jurisdiction of incorporation or organization)			(Commission File Number)			(IRS Employer Identification No.)
			451 D Street, 5th Floor
			Boston, Massachusetts 02210
			(Address of principal executive offices, including zip code)

(857) 209-0050

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

(Title of each class)			(Trading Symbol)			(Name of exchange on which registered)
Common Stock, $0.01 par value per share			ELTX			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On November 13, 2025, Elicio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 and provided corporate updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number						Exhibit Description
99.1						Press Release dated November 13, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Elicio Therapeutics, Inc.

By:

/s/ ROBERT CONNELLY

Date: November 13, 2025

Robert Connelly President and Chief Executive Officer (Principal Executive Officer)

FAQ

What did ELTX announce in this 8-K?

The company announced financial results for the quarter ended September 30, 2025 and provided corporate updates.

Which period do the ELTX results cover?

The quarter ended September 30, 2025.

What exhibit contains the detailed results for ELTX?

The full press release is furnished as Exhibit 99.1.

Is the ELTX press release considered filed for liability purposes?

No. The information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act.

What is ELTX’s trading symbol and exchange?

The common stock trades under ELTX on The Nasdaq Capital Market.

Who signed the ELTX 8-K?

It was signed by Robert Connelly, President and Chief Executive Officer.